RxDoctor Payments Data

Andrea Videlefsky, MD

Family Medicine · Marietta, GANPI 1942334255

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 96 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$499
  • Abbott$415
  • Novo Nordisk$219
  • Dexcom, Inc.$116
  • Amgen$101
  • Lilly USA, LLC$76
  • plus $332 from 11 others

What the payments were for

  • Food & beverage$1,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie29$499
Abbott20$415
Novo Nordisk15$219
Dexcom, Inc.6$116
Amgen(2 entities)5$101
Lilly USA, LLC4$76
Astellas Pharma US Inc3$69
Exact Sciences3$63
GSK2$40
Coloplast1$31
Merck2$25
Galt Pharmaceuticals, LLC1$24
Pfizer1$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$17
Currax Pharmaceuticals LLC1$16
Linus Health, Inc.1$16
Medtronic1$13

How this compares

$1,760 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$7,129
Medicare patients
22
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$22,455
Levothyroxine Sodium92$1,231
Norethindrone Acetate17$1,169
Rosuvastatin Calcium20$806
Metformin Hcl35$468
Atorvastatin Calcium58$430
Donepezil Hcl13$273
Fluoxetine Hcl20$221
Escitalopram Oxalate36$203
Amlodipine Besylate23$147
Lisinopril29$145
Losartan Potassium20$124
Alendronate Sodium15$113
Trazodone Hcl11$76
Hydrochlorothiazide18$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$219$22,45517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →